文献速递肝病消化道肿瘤与早癌

外泌体miR-335作为肝细胞癌的新型治疗策略

Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2018-01-29

肝细胞癌多在肝硬化/纤维化肝脏中发生,活化的肝星状细胞与癌细胞间存在细胞外囊泡(EV)介导的通讯。本研究证明星状细胞来源EV可装载miR-335-5p,在体外和体内被肝细胞癌(HCC)细胞摄取并传递货物,抑制HCC细胞增殖与侵袭,并在体内诱导肿瘤缩小,同时鉴定出处理后下调的miR-335靶mRNA。

要点

  • 星状细胞来源EV可装载miR-335-5p并在体外和体内被HCC细胞摄取。
  • EV-miR-335-5p在体外抑制HCC细胞增殖与侵袭,在体内诱导肿瘤缩小。
  • 鉴定出EV-miR-335-5p处理后下调的miR-335靶mRNA。

核心结论

  • 星状细胞来源EV可装载治疗性核酸并在体内递送,为HCC提供了潜在治疗策略。

研究设计与样本

  • 基础研究:基于既往EV与星状细胞研究,先提出假设再验证星状细胞来源EV装载miR-335-5p并递送至HCC细胞。

主要发现

  • 星状细胞来源EV可装载选定的miR-335-5p。
  • 该EV在体外以及体内均可被HCC细胞摄取。
  • 该EV在体外以及体内均可向受体HCC细胞提供miR-335-5p货物。
  • 该EV在体外抑制HCC细胞增殖与侵袭,在体内诱导HCC肿瘤缩小。
  • 鉴定出经EV-miR-335-5p处理后下调的miR-335靶mRNA。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) is a common and deadly cancer. Most cases of HCC arise in a cirrhotic/fibrotic liver, indicating that environment may play a paramount role in cancer genesis. Previous studies from our group and others have shown that, in desmoplastic cancers, there is a rich intercellular communication between activated, cancer-associated fibroblasts and cancer cells. Moreover, extracellular vesicles (EVs), or exosomes, have been identified as an important arm of this intercellular communication platform. Finally, these studies have shown that EVs can carry microRNA (miR) species in vivo and deliver them to desmoplastic cancers. The precise role played by activated liver fibroblasts/stellate cells in HCC development is insufficiently known. Based on previous studies, it appears plausible that activated fibroblasts produce signals carried by EVs that promote HCC genesis. In the current study, we first hypothesized and then demonstrated that stellate cell-derived EVs 1) can be loaded with an miR species of choice (miR-335-5p); 2) are taken up by HCC cells in vitro and more importantly in vivo; 3) can supply the miR-335-5p cargo to recipient HCC cells in vitro as well as in vivo; and 4) inhibit HCC cell proliferation and invasion in vitro as well as induce HCC tumor shrinkage in vivo. Finally, we identified messenger RNA targets for miR-335 that are down-regulated after treatment with EV-miR-335-5p. This study informs potential therapeutic strategies in HCC, whereby stellate cell-derived EVs are loaded with therapeutic nucleic acids and delivered in vivo. (Hepatology 2018;67:940-954).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wang F, Li L, Piontek K, et al. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology. 2018. PMID: 29023935. doi:10.1002/hep.29586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。